The risk of progressive multifocal leukoencephalopathy in patients receiving Tysabri for MS is a concern about this otherwise extremely effective therapy.
Are you a US-based MD who sees patients with neurologic disorders and who likes to write? Why not blog for NeurologyTimes.com? It's your place to be heard on topics that keep you up at night. Contact us here and we can send you the details.